Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

[Studie av en anordning som inte är godkänd eller godkänd av den amerikanska FDA]

11 juli 2026 uppdaterad av: Robert Lewandowski, Northwestern University

[Försök med utrustning som inte är godkänd eller godkänd av amerikanska FDA]

Patients will be asked to take part in this research study because they have mild-to-moderate knee osteoarthritis (OA) and were referred clinically for a procedure called Genicular Artery Embolization (GAE). Osteoarthritis is the most common form of arthritis. It occurs when the protective cartilage that cushions the ends of the bones wears down over time. The symptoms of OA include pain or aching, stiffness, decreased range of motion, and swelling. The purpose of this study is to evaluate the safety and effectiveness of GAE for the treatment of knee pain attributed to OA.

Research participants will be in this research study for about 3 years. The study includes a screening visit, GAE procedure, and six follow-up visits.

At the screening visit, a review of their medical history, demographics, and medications will be collected; physical examination will be completed; knee x-ray will be done; and two questionnaires on your knee pain will be administered. The GAE procedure will involve receiving sedation or medication to help them relax, lidocaine injected under the skin in the area of the body where catheters will be inserted into one of your arteries and then using x-ray, a catheter will be directed to the arteries supplying the lining of the knee. Then tiny microspheres will be injected into the artery to decrease the blood supply to this knee joint tissue.

The follow-up visits up to 12 months will include a focused physical examination of the treated knee, documentation of medications, and two questionnaires will be administered. The follow-up visits at year 2 and 3 will include documentation of medications and any new treatments for OA as well as completion of two questionnaires. Follow-up visits maybe conducted in clinic or remotely.

Studieöversikt

Status

Rekrytering

Betingelser

Intervention / Behandling

Studietyp

Interventionell

Inskrivning (Beräknad)

15

Fas

  • Inte tillämpbar

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studiekontakt

Studera Kontakt Backup

Studieorter

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

  • Vuxen
  • Äldre vuxen

Tar emot friska volontärer

Nej

Beskrivning

Inclusion Criteria:

  • Age 40-80 years
  • Mild-to-moderate knee OA as determined by radiographs demonstrating Kellgren- Lawrence grade 2-3
  • Self-reported pain of at least 5/10 VAS questionnaire
  • Failure of conservative therapy, such as pain medications, for at least 3 months
  • Patient must understand and sign the informed consent
  • Patient can comply with the proposed follow-up schedule
  • Patient can follow the post-operative management

Exclusion Criteria:

  • History of rheumatoid arthritis
  • Renal insufficiency precluding angiography (GFR < 50 mL/min)
  • Irreversible coagulopathy
  • Previous knee arthroplasty on the intended knee
  • Existing knee joint infection
  • Kellgren-Lawrence grade 1 or 4
  • Severe atherosclerosis as manifest by claudication and/or diminished peripheral pulses
  • Life expectancy < 6 months
  • Infectious arthritis
  • Allergy to iodinated contrast resulting in anaphylaxis
  • Pregnant or interested in becoming pregnant three months from the date of the GAE procedure
  • Involved in litigation or worker's compensation claims

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Behandling
  • Tilldelning: N/A
  • Interventionsmodell: Enskild gruppuppgift
  • Maskning: Ingen (Open Label)

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Experimentell: GAE Procedure
All participants will undergo a procedure called Genicular Artery Embolization (GAE) that will be done to try to reduce the pain in their knees.
Enhet: Embosphere Microspheres
Genicular Artery Embolization is performed by either inserting a small catheter into the artery of the upper thigh or an artery at the wrist, and with the use of x-ray, the catheter is guided to the arteries supplying the lining of the knee. Tiny particles are then injected through the catheter into these arteries, reducing the blood supply. These small particles are considered a medical device called Embosphere Microspheres. These microspheres are approved by the Food and Drug Administration (FDA) in the United States to treat hypervascular tumors; in the prostate arteries to relieve symptoms related to benign prostate hyperplasia; and to address arteriovenous malformations. The use of Embosphere Microspheres in this study is considered experimental as it has not been approved by the FDA to reduce pain associated with knee OA.

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Patient safety endpoints
Tidsram: Screening/baseline, 1, 3, and 6 months

Primary safety endpoints include:

1. Incidence and severity of adverse events (AEs). These include:

  1. Non-target embolization (e.g., distal leg)
  2. All transient intra- and post-procedure events (e.g., skin changes)
  3. Death
Screening/baseline, 1, 3, and 6 months
Objective clinical endpoints - Cone beam computed tomography
Tidsram: Immediately pre-and post-embolization
Change in enhancement on cone beam computed tomography (CT)
Immediately pre-and post-embolization
Objective clinical endpoints - VAS
Tidsram: Screening/baseline, 1, 3, 6, 12, 24 and 36 months
Change in Visual Analogue Scale (VAS), a measurement instrument where 0 represents the minimum value (e.g., no pain) and 100 (or 10) represents the maximum value (e.g., worst imaginable pain). Consequently, higher scores indicate a worse outcome (more pain/severity), while lower scores indicate a better outcome
Screening/baseline, 1, 3, 6, 12, 24 and 36 months
Objective clinical endpoints - WOMAC
Tidsram: Screening/baseline, 1, 3, 6, 12, 24 and 36 months
Change in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), a measurement instrument designed to evaluate pain, stiffness, and physical function in patients with hip or knee osteoarthritis. Higher scores on the WOMAC indicate a worse outcome (greater pain, stiffness, and functional limitations).
Screening/baseline, 1, 3, 6, 12, 24 and 36 months

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Preliminary Effectiveness - WOMAC
Tidsram: Screening/baseline, 1, 3, 6, and 12 months
Secondary endpoint will be evaluated based on existing validated pain scoring systems. The Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), a measurement instrument designed to evaluate pain, stiffness, and physical function in patients with hip or knee osteoarthritis will be utilized. Higher scores on the WOMAC indicate a worse outcome (greater pain, stiffness, and functional limitations).
Screening/baseline, 1, 3, 6, and 12 months
Preliminary Effectiveness - VAS
Tidsram: Screening/baseline, 1, 3, 6, and 12 months
Secondary endpoint will be evaluated based on existing validated pain scoring systems. The Visual Analogue Scale (VAS), a measurement instrument where 0 represents the minimum value (e.g., no pain) and 100 (or 10) represents the maximum value (e.g., worst imaginable pain) will be utilized. Consequently, higher scores indicate a worse outcome (more pain/severity), while lower scores indicate a better outcome.
Screening/baseline, 1, 3, 6, and 12 months

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Sponsor

Northwestern University

Samarbetspartners

Northwestern Memorial Hospital

Utredare

  • Huvudutredare: Robert Lewandowski, MD, Northwestern University

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

10 juli 2026

Primärt slutförande (Beräknad)

10 april 2028

Avslutad studie (Beräknad)

10 april 2031

Studieregistreringsdatum

Först inskickad

8 april 2026

Först inskickad som uppfyllde QC-kriterierna

15 april 2026

Första postat (Faktisk)

17 april 2026

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

14 juli 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

11 juli 2026

Senast verifierad

1 juli 2026

Mer information

Termer relaterade till denna studie

Nyckelord

Ytterligare relevanta MeSH-villkor

Andra studie-ID-nummer

  • STU00223591

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Ja

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera